Health Source: a subsidiary obtains approval notification for NS-041 tablet for additional depression clinical trials. There are currently no new generation drugs targeting KCNQ2/3 on the market in China.

Jiankangyuan announced that its holding subsidiary, Lizhu Pharmaceutical Factory, has received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration for the addition of the indication of "treating depression" for NS-041 tablets.